Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow

Bone Marrow Transplantation

Volumn 23, Issue 9, 1999, Pages 889-893

  Zander, A R ^a,c   Zabelina, T ^b   Kroger N ^a   Renges, H ^a   Kruger W ^a   Loliger C ^a   Durken M ^a   Stockschlader M ^d   De Wit, M ^a   Wacker Backhaus, G ^a   Bielack, S ^a   Jaburg, N ^a   Russmann B ^a   Erttmann, R ^a   Kabisch, H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Pavlow University   (Russian Federation)

^c UNIVERSITY OF HAMBURG   (Germany)

^d NONE

Author keywords

Anti thymocyte globulin; GVHD prevention; Unrelated donor

Indexed keywords

CYCLOSPORIN A; IMMUNOGLOBULIN G; METHOTREXATE; METRONIDAZOLE; THYMOCYTE ANTIBODY;

ACUTE LEUKEMIA; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CHEMOPROPHYLAXIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; ERYTHROPHAGOCYTOSIS; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MYELODYSPLASTIC SYNDROME; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SURVIVAL;

EID: 0032905094     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701745     Document Type: Article

References (38)

1. Thomas ED, Storb R, Clift RA et al. Bone-marrow transplantation. New Engl J Med 1975; 292: 832-843.
2. Goldman JM, Apperley JF, Jones L et al. Bone marrow transplantation for patients with chronic myeloid leukemia. New Engl J Med 1986; 104: 155-163.
3. Beatty PG, Clift RA, Mickelson EM et al. Marrow transplantation from related donors other than HLA-identical siblings. New Engl J Med 1985; 313: 765-771.
4. Anasetti C, Petersdorf EW, Martin PJ et al. Marrow transplantation from unrelated volunteer donors. In: Buckner CD, Clift RA (eds). Technical and Biological Components of Marrow Transplantation. Cancer Treatment and Research no. 76. Kluwer Academic: Boston, 1995, pp 137-168.
5. Blazar BR, Orr HT, Arthur DC et al. Restriction fragment length polymorphisms as markers of engraftment in allogeneic marrow transplantation. Blood 1985; 66: 1436-1444.
6. Beatty PG, Hansen JA, Longton GM et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991; 51: 443-447.
7. McGlave P, Bartsch G, Anasetti C et al. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood 1993; 81: 543-550.
8. Beatty PG, Ash R, Hows JM et al. The use of unrelated bone marrow donors in the treatment of patients with chronic myelogenous leukemia: experience of four marrow transplant centers. Bone Marrow Transplant 1989; 4: 287-290.
9. Hansen JA, Gooley TA, Martin PJ et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. New Engl J Med 1998; 338: 962-968.
10. Lee SJ, Kuntz KM, Horowitz MM et al. Unrelated donor bone marrow transplantation for chronic myeloid leukemia: a decision analysis. Ann Intern Med 1997; 127: 1080-1088.
11. McGlave PB, Beatty P, Ash R et al. Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation: results in 102 cases. Blood 1990; 75: 1728-1732. (Erratum, Blood 1990; 76: 654).
12. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. New Engl J Med 1986; 314: 729-735.
13. Hows J, Downie T, Gore S et al, on behalf of centres participating in the IMUST Study: Pretransplant serotherapy reduced GvHD without increasing relapse after unrelated donor (DU) BMT. Bone Marrow Transplant 1997; 19 (Suppl. 1): (Abstr).
14. Beelen DW, Müller KD, Schaefer UW. Intestinal bacterial decontamination and acute graft-versus-host-disease (aGvHD): first interim analysis of a prospective randomized trial. Bone Marrow Transplant 1995; 15 (Suppl. 2): 102 (Abstr. 427).
15. Beelen DW, Haralambie E, Brandt H et al. Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host-disease after sibling marrow transplantation. Blood 1992; 80: 2668-2676.
16. Klingemann HG, Barnett MJ, Reece DE et al. Use of an immunoglobulin preparation enriched for IgM (Pentaglobin) for the treatment of acute graft-versus-host disease. Bone Marrow Transplant 1990; 6: 199-202.
17. Poynton CH, Jackson S, Fegan C et al. Use of IgM enriched intravenous immunoglobulin (Pentaglobin) in bone marrow transplantation. Bone Marrow Transplant 1992; 9: 451-457.
18. Jackson SK, Parton J, Barnes RA et al. Effect of IgM-enriched intravenous immunoglobulin (Pentaglobin) on endotoxaemia and anti-endotoxin antibodies in bone marrow transplantation. EurJ Clin Invest 1993; 23: 540-545.
19. 2 fragments (5S IVIG) and Fc fragments. Evidence for post-transcriptional IL-2 modulation. Immunology 1997; 90: 212-218.
20. Nachbaur D, Herold M, Gächter A et al. Modulation of lymphocyte proliferation and cytokine release during alloimmune response in vitro by an IgM-enriched immunoglobulin preparation (Pentaglobin) for intravenous use. Immunology 1998; 94: 279-283.
21. Petersdorf EW, Longton GM, Anasetti C et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 1995; 86: 1606-1613.
22. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036-2043.
23. Zander AR, Berger C, Kröger N et al. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. Clin Cancer Res 1997; 3: 2671-2675.
24. Gluckman E, Jolivet I, Scrobohaci L et al. Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation. Br J Haematol 1990; 74: 277-281.
25. Przepiorka KM, Weisdorf D, Martin P et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
26. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
27. Szydlo R, Goldman JM, Klein JP et al. Results for allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997; 14: 1767-1777.
28. Antin JH, Bierer BE, Smith BR et al. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 1991; 78: 2139-2149.
29. Martin PJ, Hansen JA, Buckner CD et al Effects of in vitro depletion of T-cells in HLA-identical allogeneic marrow grafts. Blood 1985; 66: 664-672.
30. Mitsuyasu RT, Champlin RE, Gale RP et al. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. Ann Intern Med 1986; 105: 20-26.
31. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806-814.
32. Marmont AM, Horowitz MM, Gale RP et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-2130.
33. Storb R, Weiden PL, Sullivan KM et al. Second marrow transplants in patients with aplastic anemia rejecting the first graft: use of a conditioning regimen including cyclophosphamide and antithymocyte globulin. Blood 1987; 70: 116-121.
34. Storb R, Etzioni R, Anasetti C et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994; 84: 941-949.
35. Horstmann M, Stockschläder M, Krüger W et al. Cyclophosphamide/antithymocyte globulin conditioning of patients with severe aplastic anemia for marrow transplantation from HLA-matched siblings: preliminary results. Ann Hematol 1995; 71: 77-81.
36. Eiermann H, Lambrecht P, Zander AR. Monitoring anti-thymocyte globulin (ATG) in bone marrow recipients. Bone Marrow Transplant 1999; 23: 779-781.
37. van Bekkum DW, Roodenburg J, Heidt PJ et al. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Natl Cancer Inst 1974; 52: 401-404.
38. Sullivan KM, Kopecky KJ, Jocom J et al. Immunomodulatory and antimicrobial efficiency of intravenous immunoglobulin in bone marrow transplantation. New Engl J Med 1990; 323: 705-712.